Flora Moujaes, Jie Lisa Ji, Masih Rahmati, Joshua B Burt, Charles Schleifer, Brendan D Adkinson, Aleksandar Savic, Nicole Santamauro, Zailyn Tamayo, Caroline Diehl, Antonija Kolobaric, Morgan Flynn, Nathalie Rieser, Clara Fonteneau, Terry Camarro, Junqian Xu, Youngsun Cho, Grega Repovs, Sarah K Fineberg, Peter T Morgan, Erich Seifritz, Franz X Vollenweider, John H Krystal, John D Murray, Katrin H Preller, Alan Anticevic
BACKGROUND: Ketamine has emerged as one of the most promising therapies for treatment-resistant depression. However, inter-individual variability in response to ketamine is still not well understood and it is unclear how ketamine's molecular mechanisms connect to its neural and behavioral effects. METHODS: We conducted a single-blind placebo-controlled study, with participants blinded to their treatment condition. 40 healthy participants received acute ketamine (initial bolus 0...
April 17, 2024: ELife